ATE506353T1 - Die hiv-replikation inhibierende indan- substituierte pyrimidine - Google Patents

Die hiv-replikation inhibierende indan- substituierte pyrimidine

Info

Publication number
ATE506353T1
ATE506353T1 AT04737251T AT04737251T ATE506353T1 AT E506353 T1 ATE506353 T1 AT E506353T1 AT 04737251 T AT04737251 T AT 04737251T AT 04737251 T AT04737251 T AT 04737251T AT E506353 T1 ATE506353 T1 AT E506353T1
Authority
AT
Austria
Prior art keywords
indane
hiv replication
substituted pyrimidines
replication inhibiting
inhibiting
Prior art date
Application number
AT04737251T
Other languages
English (en)
Inventor
Jerome Guillemont
Elisabeth Pasquier
Jan Heeres
Kurt Hertogs
Eva Bettens
Paulus Lewi
Jonge Marc De
Lucien Koymans
Frederik Daeyaert
Hendrik Vinkers
Paul Janssen
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE506353T1 publication Critical patent/ATE506353T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04737251T 2003-02-20 2004-02-20 Die hiv-replikation inhibierende indan- substituierte pyrimidine ATE506353T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
PCT/EP2004/050175 WO2004074261A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (1)

Publication Number Publication Date
ATE506353T1 true ATE506353T1 (de) 2011-05-15

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04737251T ATE506353T1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende indan- substituierte pyrimidine
AT04737252T ATE361915T1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende pyrimidine und triazine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04737252T ATE361915T1 (de) 2003-02-20 2004-02-20 Die hiv-replikation inhibierende pyrimidine und triazine

Country Status (27)

Country Link
US (2) US7585870B2 (de)
EP (2) EP1603887B1 (de)
JP (2) JP4586013B2 (de)
KR (2) KR20050094896A (de)
CN (2) CN100572364C (de)
AP (1) AP2005003373A0 (de)
AR (2) AR044500A1 (de)
AT (2) ATE506353T1 (de)
AU (2) AU2004213186B2 (de)
BR (2) BRPI0407741B8 (de)
CA (2) CA2516699C (de)
CL (2) CL2004000306A1 (de)
CY (1) CY1106788T1 (de)
DE (2) DE602004032321D1 (de)
DK (1) DK1597238T3 (de)
EA (2) EA011256B1 (de)
ES (1) ES2287734T3 (de)
HR (2) HRP20050820A2 (de)
IL (2) IL169596A (de)
MX (2) MXPA05008866A (de)
MY (1) MY138308A (de)
NO (2) NO20054312L (de)
NZ (2) NZ542428A (de)
PL (2) PL226954B1 (de)
PT (1) PT1597238E (de)
TW (2) TW200510339A (de)
WO (2) WO2004074261A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1534286B1 (de) 2002-07-29 2009-12-09 Rigel Pharmaceuticals, Inc. VERFAHREN ZUR BEHANDLUNG ODER PRûVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
DK1656372T3 (da) 2003-07-30 2013-07-01 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
WO2006024034A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP5225079B2 (ja) 2005-06-08 2013-07-03 ライジェル ファーマシューティカルズ, インコーポレイテッド Jak経路の阻害のための組成物および方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
EP1951684B1 (de) 2005-11-01 2016-07-13 TargeGen, Inc. Biarylmetapyrimidinkinaseinhibitoren
EP1991532B1 (de) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung des jak-pfades
EP2781510B1 (de) * 2006-12-29 2016-12-14 Janssen Sciences Ireland UC Hiv-hemmendes 5,6-substituiertes pyrimidin
BRPI0720858B8 (pt) * 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US7737157B2 (en) * 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
AU2009290474A1 (en) 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
SI2406253T1 (sl) 2009-03-11 2013-09-30 Pfizer Inc. Derivati benzofuranila, uporabljeni kot inhibitorji glukokinaze
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2018019204A1 (zh) * 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
PL3966207T3 (pl) 2019-05-10 2024-03-04 Deciphera Pharmaceuticals, Llc Fenyloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
CN114072397A (zh) 2019-05-10 2022-02-18 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NZ322907A (en) 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0945447A1 (de) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
HU230394B1 (hu) * 1998-11-10 2016-04-28 Janssen Pharmaceutica N.V. HIV-vírus szaporodását gátló pirimidin-származékok
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
BRPI0014271B1 (pt) * 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
AU2002216650A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003066099A1 (fr) * 2002-02-05 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Derives de 2,4,6-triamino-1,3,5-triazine
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CN1665789A (zh) * 2002-06-28 2005-09-07 山之内制药株式会社 二氨基嘧啶酰胺衍生物
EP1534286B1 (de) * 2002-07-29 2009-12-09 Rigel Pharmaceuticals, Inc. VERFAHREN ZUR BEHANDLUNG ODER PRûVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CL2004000306A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.

Also Published As

Publication number Publication date
CA2516589A1 (en) 2004-09-02
CL2004000306A1 (es) 2005-04-08
IL169647A (en) 2013-05-30
HRP20050821A2 (en) 2006-11-30
AU2004213187B2 (en) 2009-11-05
US20060194804A1 (en) 2006-08-31
CY1106788T1 (el) 2012-05-23
PL226954B1 (pl) 2017-10-31
EP1603887A1 (de) 2005-12-14
KR20050094896A (ko) 2005-09-28
AU2004213187A1 (en) 2004-09-02
EA200501327A1 (ru) 2006-02-24
TW200500346A (en) 2005-01-01
ES2287734T3 (es) 2007-12-16
BRPI0407741B8 (pt) 2021-05-25
WO2004074262A1 (en) 2004-09-02
CA2516589C (en) 2012-04-17
BRPI0407741A (pt) 2006-02-14
NZ541601A (en) 2007-09-28
ATE361915T1 (de) 2007-06-15
CN1751030A (zh) 2006-03-22
AU2004213186A1 (en) 2004-09-02
EA011256B1 (ru) 2009-02-27
KR20050099994A (ko) 2005-10-17
PL378136A1 (pl) 2006-03-06
NO20054312L (no) 2005-11-16
IL169596A0 (en) 2007-07-04
DK1597238T3 (da) 2007-09-10
US7442705B2 (en) 2008-10-28
IL169647A0 (en) 2007-07-04
MXPA05008866A (es) 2005-10-05
HRP20050820A2 (en) 2006-11-30
AP2005003373A0 (en) 2005-09-30
EP1597238A1 (de) 2005-11-23
BRPI0407732A (pt) 2006-02-14
CN1751031A (zh) 2006-03-22
BRPI0407741B1 (pt) 2018-05-29
DE602004006383D1 (de) 2007-06-21
CN1751031B (zh) 2010-07-21
JP4586013B2 (ja) 2010-11-24
MY138308A (en) 2009-05-29
EP1597238B1 (de) 2007-05-09
TW200510339A (en) 2005-03-16
WO2004074261A1 (en) 2004-09-02
CA2516699A1 (en) 2004-09-02
PL227295B1 (pl) 2017-11-30
AR044500A1 (es) 2005-09-14
JP4586014B2 (ja) 2010-11-24
MXPA05008867A (es) 2005-10-05
PT1597238E (pt) 2007-08-08
NO20054311D0 (no) 2005-09-19
CA2516699C (en) 2011-07-12
US20060142571A1 (en) 2006-06-29
EA010423B1 (ru) 2008-08-29
DE602004032321D1 (de) 2011-06-01
NO20054312D0 (no) 2005-09-19
EA200501326A1 (ru) 2006-02-24
CN100572364C (zh) 2009-12-23
PL378064A1 (pl) 2006-02-20
AR044499A1 (es) 2005-09-14
NO20054311L (no) 2005-10-27
DE602004006383T2 (de) 2008-01-10
US7585870B2 (en) 2009-09-08
EP1603887B1 (de) 2011-04-20
NZ542428A (en) 2007-11-30
AU2004213186B2 (en) 2009-10-01
JP2006518356A (ja) 2006-08-10
IL169596A (en) 2017-02-28
JP2006518357A (ja) 2006-08-10
CL2004000303A1 (es) 2005-04-08

Similar Documents

Publication Publication Date Title
ATE506353T1 (de) Die hiv-replikation inhibierende indan- substituierte pyrimidine
ATE500254T1 (de) Die replikation von hiv hemmende purinderivate
CY2012013I2 (el) Παραγωγα πυριμιδινης που αναστελλουν τον hiv
NO20044374L (no) Pyrimidinderivater
ATE529412T1 (de) Herbizide pyrimidine
IL180959A0 (en) Hiv inhibiting 5-heterocyclyl pyrimidines
IL180963A0 (en) Hiv inhibiting bicyclic pyrimidine derivatives
ZA200702655B (en) HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
MA28824B1 (fr) Derives de pyrimidine
MA28813B1 (fr) Derives de pyrimidine
ATE542802T1 (de) Hiv-inhibierende 5-substituierte pyrimidine
NO20042742L (no) Pyrimidinforbindelser
IL172848A0 (en) 2-substituted pyrimidines
NO20054141D0 (no) Substituerte 2-(diaza-bicykloalkyl)pyrimidonderivater
IL172845A0 (en) 2-substituted pyrimidines
TWI315199B (en) Hiv replication inhibiting pyrimidines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties